Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Kost

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Pharmacology|April 29, 2008
Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF intervalM Iwamoto, J T Kost, G C Mistry, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2008
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjectsMatt S Anderson, Thomas N Kakuda, William Hanley, et al.
Antimicrobial Agents and Chemotherapy|July 16, 2008
Lack of a significant drug interaction between raltegravir and tenofovirLarissa A Wenning, Evan J Friedman, James T Kost, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2009
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokineticsMarian Iwamoto, William D Hanley, Amelia S Petry, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2008
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravirMarian Iwamoto, Larissa A Wenning, Amelia S Petry, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning, A S Petry, J T Kost, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Pharmacology|April 29, 2008
Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF intervalM Iwamoto, J T Kost, G C Mistry, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2008
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjectsMatt S Anderson, Thomas N Kakuda, William Hanley, et al.
Antimicrobial Agents and Chemotherapy|July 16, 2008
Lack of a significant drug interaction between raltegravir and tenofovirLarissa A Wenning, Evan J Friedman, James T Kost, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2009
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokineticsMarian Iwamoto, William D Hanley, Amelia S Petry, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2008
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravirMarian Iwamoto, Larissa A Wenning, Amelia S Petry, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning, A S Petry, J T Kost, et al.
Pageof 2